Immix Biopharma, Inc. Research And Development Expense

• Immix Biopharma, Inc. showed an increase of +44.0% in Research And Development Expense from 2024 to 2025.
• This data is from Immix Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 25, 2026.
• XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 6 years of available data (2020 to 2025), Immix Biopharma, Inc.'s Research And Development Expense has grown by 6,451.9%.
• Historical annual values: Fiscal year 2025: $16.26 million | Fiscal year 2024: $11.29 million | Fiscal year 2023: $8.74 million | Fiscal year 2022: $4.20 million | Fiscal year 2021: $126.5 thousand | Fiscal year 2020: $248.1 thousand.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026